Guided Therapeutics Inc (GTHP)

[GetSeriousOK]

When the stock closes over 15 cents, you say nothing, but when the stock closes under 15 cents, you say "it can't rise above 15 cents." It's just silly.

There's 45,000 on the BID at .135 right now -- where are your sellers?

And why the FUD anyway? This stock is WAY under the radar. Nobody is reading this MB except investors who've already heard your FUD message. There's nobody new here. Maybe you should save the FUD bullshit until there's some news.

[myjog]

The oh my god is for the sellers’ sentiment to dump 1K stock even at 0.132$ bargain basement price.
The price goes above 0.15$ but remains there for a very short period of times. The price immediately falls back below 0.15$.
What’s going to happen in next several weeks?
Unless bid goes above 0.15$ it’s next to impossible for this stock price to climb above 0.15$

[GetSeriousOK]

that trade at 0.132 was for 1,002 shares. Total: $132.26

does that really warrant the exclamation "oh my god?"

If that seller from June 8 2023 came back and dumped under a dime again, that would warrant an "oh my god" from you (and a "hallelujah!" from me), but a trade costing $132.26 is not a reason to lose you cool.

If you're going to freak out and exclaim "oh my god" every time there's a $125 trade under 15 cents, you might want to get some anxiety medication to help you survive the next several weeks.

[GetSeriousOK]

Except for when it goes above 0.15

Which it has done several times in the past couple of weeks.

[myjog]

oh my god. Seller at 0.1320$
Sellers are literally selling at any bargain basement / salvage price they can get. This is very bad for the stock.
It appears like this stock will not go above 0.15$ ever.

[myjog]

Each & every uptick in bid is taken. However it seems like at least today there’s some support. Till there are sellers at bargain basement prices, it’s very challenging for this stock price to go up.

[GetSeriousOK]

pacjd, I have no problem with you on a personal level, and I wish giul the best in their upcoming lawsuit. I'm just trying to do some due diligence.

The current standard of care is still the pap smear, although HPV testing is gaining traction. A pap smear is kind of intrusive -- insert a speculum, expose the cervix, and use a brush to gather cells. You say the LuViva scan is "old tech" but the pap smear is older -- invented in 1920 and made available in the 1950's. So I'm not sure what you're trying to say when you say this:

the real scam is GTHP technology is very old and countries like China ect. don t consider the current sound reliable way of testing that intrusive neither does any DR in the USA.

. Why would that prevent doctors from using the LuViva scan, and why did you single out China? Read this about Cervical Cancer in China:

The burden of cervical cancer in China
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530827/

"The age-standardized incidence of cervical cancer in China increased from 1990 to 2019."

[GetSeriousOK]

In your mind, what did Faupel and/or Blumberg do that was illegal and/or a violation of SEC regulations?

In your mind, what did GTI do that was illegal and/or a violation of SEC regulations?

[GetSeriousOK]

the explanations are in the form 4's.

Perhaps you should ask myjo for an explanation?

You could look here :

https://www.otcmarkets.com/stock/GTHP/disclosure

Notice that all SEC transactions in the past two years are BUYS/exercises by insiders. The insiders own a lot of this stock. It was all priced above market with the exception of Blumberg's most recent transaction.

In the most recent Form 4, Blumberg combined some warrants at .25 that were expiring on 12/31 into fewer warrants at .12 and exercised them. He gave himself a really good deal this last time. That was the only one priced below market.

[myjog]

Can someone take a look at couple of Form-4s submitted by Blumberg recently and explain what’s going on?
Did he exercise his warrants? Did he acquire or sold stock below market price or above market price?

[myjog]

There are sellers even at a bargain basement price of 0.1333$.
It appears that this stock has no future.
Impossible for this stock to go above 0.15$

[GetSeriousOK]

This is a FDA play.

I've had success with FDA plays where the drug or device was rejected more than once by the FDA. The investing public tends to undervalue those and when/if those companies get FDA approval/clearance, the stock really pops.

There are no guarantees in biotech, especially in penny biotech. This is gambling and anyone who says different is lying or ignorant. There's no guarantee that the FDA won't reject the application AGAIN, and if that happens this company goes belly up. It pretty much went belly up after the last rejection but the CEO (Cartwright) somehow replaced the toxic financing and pulled a phoenix from the ashes.

This is my current favorite biotech pennystock gamble. Those who don't like it don't have to participate.

Will the LuViva Scan make Guided a lot of money after FDA clearance? Frankly, I don't care. That's an entirely different play, IMO. I've seen dozens of biotechs get FDA approval/clearance only to discover they couldn't sell the product. (Dendreon might be the most famous.)

But that's putting the cart in front of the horse. I'm here for the FDA play. Study results first, then FDA submission, then FDA decision.... it's not happening tomorrow. The PPS reflects this.

I'm not mentioning SMI because I don't believe SMI has any money. If they prove me wrong and make a payment... icing on the cake. And if they don't, their clinical study won't hurt Guided's chances with the USFDA.

The lawsuit against Faupel and Blumberg is unrelated chatter. The disputed loan amount was only $64,000 and GTHP is not a defendant. The outcome of that case is not going to affect GTHP but I guess there's not much else to talk about right now.

Are Faupel and Blumberg saints? Of course not. Should you believe anything a pennystock biotech CEO tells you over the phone? No you should not. Welcome to penny biotech. I've seen, and made money on, a LOT WORSE.

[GetSeriousOK]

What does this mean?

...don t consider the current sound reliable way of testing that intrusive neither does any DR in the USA.

Seriously, can you reword that so it makes sense?

Do you think doctors in the USA have experience with the technology of the LuViva scan? How would they get that experience since it's not cleared by the FDA?

[myjog]

You appear to be confident about technology & prospects of this company. Then do you think that current stock price is appropriately priced/valued?

[2themoon1]

Lastly, Unless your DR walks on water...which I'm sure he/she doesn't, one must ask themselves, would such prestigious sites in the US agree to start a study if the technology was dated and inferior to that of the current standard of care???? NO THEY WOULDNT!!!!!! Also, would Dr. Kong Beihua of Qilu Hospital at Shandong University and Dr. Sui Long, Director of the Gynecology Hospital at Fudan University. Professor Kong is Vice Chairman of the Chinese Society of Obstetrics and Gynecology Society who are widely respected and in the top of their field get involved in a technology that, once again, is dated and inferior??? I THINK NOT.
You really should go back to the drawing board and do your homework this time before you come back and embarrass yourself again.

[2themoon1]

If your "mere opinion" came from a Dr...then it is not your mere opinion!!! Also not impressive that you know a Dr...i'm pretty sure everyone here knows 1 or 2 themselves. Ask yourself if your DR is a specialist in this field. Lastly...as a shareholder and supporter of the success of GTHP, may i kindly request that you redirect your uninformed/false verbal diarrhoea to another chat site that actually cares.

[Pacjd]

Get should I ask if your name is slick Rick Richard P. Blumberg and his stock marketing business or Mark Faupel CEO President, as my deceased dad would say dirty water seeks its own level. Plus the real scam is GTHP technology is very old and countries like China ect. don t consider the current sound reliable way of testing that intrusive neither does any DR in the USA. Just letting the uninformed know. FYI, my mere opinion comes from a DR.

[myjog]

Why anyone would sell 8K shares at bargain basement price of 0.1401?

[GetSeriousOK]

Good luck with that, Paul. Knock yourself out.

[Pacjd]

FYI, Giul LlC's attorney has outlined potential claims which GIUL LLC might file a lawsuit directly against GTI - GTHP or in the alternative Giul LlC might initiate a SEC complaint against Faupel and Blumberg.

[Pacjd]

Owed to Shenghou Medical, LLC now k2 on what you called a non disclosed royalty type payment agreement, and by coincidence upper managers of GTHP are being sued by GIUL for non disclosures which are a significant part of GIUL's unfair and deceptive trade practices law suit against Mark Fauple now President and CEO and Richard Blumberg Director at GTHP.

[GetSeriousOK]

Yes but were talking about monies paid by SMI to GTHP that were then owed to Shenghuo.

But again, I don't care about China or your claims against Faupel and Blumberg. I only care about the clinical trials being completed, the FDA submission, and FDA approval. I believe the FDA will approve the application THIS TIME.

IF GTHP gets any money from SMI, that would be icing on the cake. I don't think SMI has that kind of money. But IF the doctors who ran that study publish their results, that is a huge win for GTHP because they could then submit that study with their US study.

[GetSeriousOK]

I don't have a beef with GTHP over any of the Chinese agreements. I learned long ago not to invest in China Hype. I did not buy this stock because of anything that might or might not happen in China.

Or Turkey or Africa or anywhere but the USA.

[GetSeriousOK]

You're asking me why GTHP signed an agreement with Shenghuo? I ask you, why not, in absence of a better Chinese representative?

All I'm saying is that maybe you have a beef with Faupel and Blumberg but GTHP is not a defendant so GTHP doesn't get harmed or helped by the outcome of that case.

[Pacjd]

In the Summary Judgment decision the Superior Court Judge acknowledged that Giul, LLC's monies were paid to GTHP, by Shenghou Medical LLC.

[Pacjd]

Get my offer still stands:

GetSerious just have your attorney send Mark Faupel and Richard Blumberg a certified letter inquiring which it was, I will pay your legal bill and then you will know i was only referring to your facts not being correct.. I have no problem with you on a personal level and when you come to realize what I am saying is true maybe you will spear head and SEC complaint for non disclosures.

Perhaps they will not produce the royalties type agreement whereby Shenghou Medical LlC did in fact receive monies from the monies GTHP was paid from SMI, and the shareholders of GTHP will have additional claims or a beef for an SEC Complaint for non disclosures.

[Pacjd]

Giul LlC's law suit for their engaging in unfair and deceptive trade practices covers Mark Faupel and Richard Blumberg not making adequate disclosures, on in particular is that they did not disclose that Shenghou Medical, LLC did not have the expertise to satisfy its licensing agreement requirements with GTHP. So why was that agreement granted by GTHP to Shenghou Medical, LLC which had no expertise and was Managed by Blumberg, and Blumberg and Faupel had ownership interests in Shenghou Medical, LLC.

[GetSeriousOK]

Just curious, Paul: How much are you asking in damages?

The disputed loan is $64,000. How much more $$$ might Faupel and Blumberg be forced to pay if they lose all the remaining claims?

[GetSeriousOK]

GTHP is not a defendant in that case.

[GetSeriousOK]

That attorney didn't file a complaint against GTHP.

[Pacjd]

2) ALLEDGES that: Mr. Blumberg, Esq., as an attorney is an officer of the court in Washington State and is held to a higher standard, and attorney Blumberg, under the pains and penalties of perjury gave his deposition testimony, (as a defendant in Civil Litigation, in Massachusetts Superior Court, GIUL, LLC vs Richard P. Blumberg), in which attorney Blumberg lied and made numerous false statements, specifically stating that he attorney Blumberg a Stanford Law Graduate, did not know the plain English definition and meaning of the word “THEY” or its context use, in an email where it was clearly being used to refence “they” the potential investor (GIUL, LLC) was a lender and had lender status. In said deposition it was proven that attorney Blumberg was in fact the original author of said email containing the word “THEY” to describe the potential investor as a lender having lender status.

It is also alleged that attorney Blumberg made numerous other false statements and misrepresentation to the manager of GIUL, LLC, Plaintiff, in Plaintiff’ s ordinary business dealings with attorney Blumberg, as manager of Shenghou Medical LLC now known as “K2”.

3) ALLEDGES that: Mr. Blumberg, Esq., as Manager of Shenghou Medical, LLC, the receiver of GIUL, LLC Plaintiff’s funds, controlled Shenghou’s Bank accounts and received from GIUL’s fund in fundraising via the Federal Wire System. It is alleged based on the below, that attorney Blumberg committed Federal Wire Fraud against the plaintiff GIUL, LLC.

[Pacjd]

A retired attorney has filed a complaint against attorney Richard Paul Blumberg, now a Director of Guided Therapeutics, Inc (“GTI”), ticker symbol: GTHP, to revoke Blumberg’s license to practice law in Washington State.

Press release: 12-5-23, 12:45 PM ET Legal Newswire POWERED BY LAW.COM

The filed disbarment complaint against attorney Richard Paul Blumberg is based on:


1) Mr. Blumberg, Esq., in connection with fundraising, engaged in conduct that violated Massachusetts securities laws, Massachusetts law barring unfair and deceptive trade practices, and Massachusetts law against conspiracy.

Messrs. Mark L. Faupel, now President and Chief Executive Officer of GTI GTHP, as well as Richard P. Blumberg, Esq., an attorney from the Seattle, Washington area, Blumberg now a Director of GTI GTHP, and Blumberg, Esq., and the other defendants brought a motion for summary judgment to try and end GIUL’s claims against them without trial. A judge of the Massachusetts Superior Court has now ruled denying the motion for summary judgment as to the securities claim, the unfair and deceptive trade practice claim, and the conspiracy claim and permitted these three claims to go to trial.

[GetSeriousOK]

I acknowledge that what I believe to be the facts are only what is contained in GTHP's filings with the SEC.

I am really only trying to participate in a discussion, and I appreciate your participation. It's an academic duscussion for me because I don't think SMI is going to pay Guided 2.2 million. Frankly, I'm only here for the FDA play in the USA -- I don't have much faith in the "China Play" of SMI. They might actually submit an application to the NMPA (fka CFDA), but I'd be very surprised if SMI has $2.2 million USD. They look like a small entity that does little more than manufacture glass blood collection tubes.

I do think the Chinese study will help Guided get US FDA approval. Can't hurt.

I will try to follow the Conte trial in March. You should keep us posted. Thanks!

[Pacjd]

SMI was promising to pay $1 Million so they got what they wanted a New Direct Licensing Agreement with GTHP.

Shenghou Medical LLC now know as K2 to relinquish and give up their contractual rights under the original Licensing Agreement got a Royalty Type payment arrangement either in the form of their Existing Original Licensing Agreement being amended or Shenghou Medical LLC, now K2 getting an new Royalty Type Payment Agreement (I cannot remember which form).

I will state under the pains and penalties of perjury that when SMI paid monies to GTHP, GTHP then subsequently as required in their agreement with Shenghou Medical LLC, now K2 did in fact receive royalty type payments from GTHP which GTHP was required to pay the same per its agreement with Shenghou Medical, LLC now K2.

GetSerious just have your attorney send Mark Faupel and Richard Blumberg a certified letter inquiring which it was, I will pay your legal bill and then you will know i was only referring to your facts not being correct.. I have no problem with you on a personal level and when you come to realize what I am saying is true maybe you will spear head and SEC complaint for non disclosures.

[GetSeriousOK]

that "royalty interest" you describe is not documented anywhere and it contradicts what GTHP filed with the SEC.

So you're asking me to believe YOU, an anonymous poster on a message board, instead of the legal SEC filings of a publicly traded company.

You see how that would be hard for me to do, right?

I think Shenghou gave up contractual rights simply because they couldn't fulfill their part of the contract. That doesn't entitle them to royalty payments or any other kind of payment.

If Shenghou "found SMI" to keep their GTHP agreement alive, they would sub-contract with SMI and keep dealing with GTHP themselves. That didn't happen. SMI is dealing directly with GTHP. Shenghou is not part of that agreement in any way. At least, that's what the SEC filings say. You want me to believe that GTHP is lying in their SEC filings, and without proof, I am not going believe that.

No point in discussing this further unless you want to match the proof I offered from the SEC filings with contradicting proof that there's a legal agreement between Shenghuo and GTHP stipulating that Shenghuo gets a royalty from SMI payments.

[Pacjd]

Shenghou Medical, LLC shareholders have always been comprised of Richard Blumber, who has also always been its manager, and Mark Faupel, who has always been a shareholder and at one point in time also a manager. Shenghou Medical LLC, now know as K2 had the original license with GTHP, despite having no expertise to satisfy its obligation to perform the same so it found SMI to enter into a new arrangement with GTHP. Because Shanghou Medical LLC gave up contractual rights it received a royalty interest from any monies GTHP would receive from SMI. GTHP did in fact receive monies from SMI and subsequently GTHP then did in fact paid a portion of the monies it received out to Shenghou Medical LLL now know as K2. GTHP is contractually obligate to pay Shenghou Medical, LLC now as "K2" royalty type payments on any monies GTHP receives from SMI.

I am not responsible for others failures to make required SEC disclosures.
I am a shareholder of GTHP so perhaps you are right with voicing shareholder concerns for non disclosures and any ramifications for the such non disclosures if that proves to be the case.

[GetSeriousOK]

You criticize me for not believing the word of an anonymous poster on a message board. Sorry, but that's just how I am. I choose to believe GTHP's filings with the SEC until I see contradicting proof.

(Well, sort of anonymous -- I think we know better, don't we? Who would post insider information from the Conte case other than...... ????)

You insist that "SMI owed GTHP $1 Million" but where is that documented? That would be booked as uncollected debt on the balance sheet. Where in GTHP's filings is this booked?

GTHP owed Shenghou money for loans, so it doesn't surprise me that GTHP paid Shenghuo money when they had it, but where is the contractual agreement that says GTHP is OBLIGATED to pay Shenghuo money when/if SMI makes a payment? That makes no sense. Maybe Faupel and/or Blumberg make this claim but I won't believe that until I see it documented in GTHP's filings with the SEC. That contradicts what they DID say in their filings.

The Conte lawsuit is for a $64,000 loan that is under dispute as to whether it was convertible or not. (Conte signed a contract without reading it -- who would do that? Seems shaky to me but the judge is going to allow the case to go to trial.) That's between Faupel, Blumberg, and Conte. GTHP is not involved.

[GetSeriousOK]

What you are describing contradicts the description GTHP filed with the SEC in every 10-Q and 10-K and prospectus filed in the past five years.

So either GTHP lied in all their SEC filings and you are now disclosing insider information, which is illegal....

OR

You are confused.

I'm assuming you're disclosing information from the depositions from the Conte case. If you're going to disclose that information, quote the depositions directly. I think the problem here lies in a faulty interpretation of what Faupel and Blumberg actually said.

[Pacjd]

SMI owed GTHP $1 Million and SMI only made partial payments on this (Mark Faupel and Richard Blumberg refused to provide me with the full amount of payments made by SMI to GTHP) SMI did not pay the full $1 Million amount to GTHP, and out of the monies GTHP did in fact receive, GTHP subsequently made payments to Shenghou Medical LLC, now know as K2, as GTHP is obligated to do the same as I have stated.

If you say such should have been disclosed and was not, is that a big surprise to you given that Mark Faupel and Richard Blumberg are each individually being sued in Massachusetts for unfair and deceptive trade practices in Massachusetts for conduct they engaged in against one of the share holder owners, GIUL, LLC in Shenghou Medical, LLC. That lawsuit on it own should speak for its self. I am not going to continue to engage with your misconception which you have based your opinion on.

[GetSeriousOK]

Those are not undisputed facts -- they are misconceptions on your part, IMO.

What you are describing would be an agreement between SMI and Shenguo. You are describing Shenghuo hiring SMI as a sub-contractor. In that arrangement, SMI would pay Shenghuo directly.

If it were true that "GTHP is obligated to share fees (it receives from SMI) with Shenghou Medical, LLC " then that would be described in GTHP's filings. It is not. You're asking us to believe something that is undocumented simply because you say it's true. Sorry, can't do that.

We understand that you have an axe to grind with Faupel and Blumberg. You must be the guy who is suing them. What do you gain by bashing GTHP on this MB? How does that increase your odds of winning the court case against Faupel and Blumberg?

[GetSeriousOK]

SMI may have paid GTHP some money but it wasn't much -- if you disagree, name the quarter in which SMI's payments show up on the balance sheet. And that $1 million was part of the agreement between Shenghuo and GTHP, not SMI and GTHP.

GTHP doesn't owe Shenghou any money that is contingent upon SMI making a payment. SMI and Shenghuo are completely independent of each other. Any money paid by SMI to GTHP is the property of GTHP, not the property of Blumfeld or Faupel. If GTHP want to repay Shenghup for some past loans, thry can, but they are not contractually obligated to do so if/when SMI pays anything.

Faupel and Blumberg may or may not have to pay Conte some money but GTHP is not a defendant in Conte's lawsuit.

I understand that you are upset about (and perhaps involved in) the Conte case. Perhaps a different message board would be a better place to complain about that matter.

[Pacjd]

Additional FACTS, SMI did pay some of the $1 million to GTHP and out those monies GTHP DID IN FACT MAKE CORRESPONDING PAYMENTS TO Shenghou Medical, LLC now know as K2, at one time Faupel was both an owner and manager of this entity now he is only an owner, at all times Richard Blumberg has been both an owner and manager of Shenghou Medical, LLC now know as K2.

[Pacjd]

That Shenghou is the original license holder with GTHP and because Shenghou had no expertise to satisfy its obligation under the same, Shenghou had to find a substitute like SMI. SMI became a new Licensee and substituted into a New Licensing Agreement between SMI and GTHP, under which SMI was to pay GTHP $ I million which it never fully paid. Because Shenghou Medical, LLC (now K2) gave up rights it became untitled to receive and participate in fees SMI is obligated to pay to GTHP,.

When and if GTHP collects fees under its agreement with SMI, GTHP is obligated to share fees with Shenghou Medical, LLC now K2, which Richard Blumberg is both a manager and owner in K2. Mark Faupel at one time was both a manager and owner in K2, now Faupel is just an owner in K2.

GTHP is obligated to share fees (it receives from SMI) with Shenghou Medical, LLC now K2. Those are undisputed facts.

[GetSeriousOK]

You've got that all wrong. GTHP doesn't have to give Shenghuo a dime of any SMI payment. Shenghuo and SMI are completely independent of each other. GTHP doesn't owe Shenghuo any royalties or percentages because Shenghuo didn't fulfill their part of the agreement.

On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee).

That's the $1 million you were talking about before that "Faupel didn't make SMI pay," isn't it? SMI had nothing to do with that $1 million. That was an optional payment that Shenghuo had the choice of making or not, and they did not, which means GTHP doesn't have to make the described future 2% payments to Shenghuo.

[Pacjd]

IF SMI pays, GTHP, then in turn GTHP has to pay some monies out to Shenghou, LLC now know as "K2" the original license holder.

More importantly Shenghou, LLC now K2 did not have the expertise to satisfy the terms of the original license agreement with GTHP (so why would that agreement have been entered into?) and Shenghou now K2 had to find a substitute like SMI or else Shenghou LLC (now K2) would loose the License Agreement with GTHP.

The really fishy smell here is that both Mark Faupel and Richard Blumberg are owners of Shenghou LLC (now K2). I will leave it at that for now!

[GetSeriousOK]

EPS and PE for a developmental biotech without earnings..... yeah right.

You can stop the trolling. Everyone here is on to your game.

[myjog]

Anyone would like to comment?
If SMI pays GTHP 2.2 ML$, then how much will be their revenue, how much will be their net income? How much will be their EPS? What’s the PE for GTHP/this sector? & then how much (potentially) high the stock price may go?

[GetSeriousOK]

Homey don't play dat game.

[myjog]

What I meant was, in this entire year the bid has been stubbornly sitting at either 0.126$ or 0.136$
So assuming SMI pays 2./ ML$ to GTHP then will bid will go up than 0.15$ and subsequently the stock price? If yes, then how much (potentially) high it can go?

[GetSeriousOK]

it's above 15 cents NOW.